口服肽治疗药物研发商Pinnacle Medicines宣布超额认购8900万美元B轮融资，以推进其研发管线进入临床试验阶段-动脉网

Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials

PR Newswire 等信源发布 2026-03-26 19:30



可切换为仅中文







Financing co-led by LAV and Foresite Capital with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investors including OrbiMed

融资由礼来亚洲基金和远见资本共同领投，泉创资本、翰康资本、RA资本管理、Logos资本以及包括奥博资本在内的现有投资者参投。

Company has raised $134 million to date following incubation by OrbiMed and other healthcare specialist investors

公司迄今为止已筹集了1.34亿美元，由OrbiMed和其他医疗保健专业投资者孵化。

Proceeds will support advancement of oral peptide pipeline through clinical proof of concept

收益将支持口服肽管道通过临床概念验证的进展。

SHANGHAI and DOYLESTOWN, Pa.

上海和宾夕法尼亚州多伊尔斯敦

，

March 26, 2026

2026年3月26日

/PRNewswire/ --

Pinnacle Medicines

巅峰医药

('Pinnacle' or 'the Company'), a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of an oversubscribed $89 million Series B financing. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investors including OrbiMed..

（“Pinnacle”或“公司”），一家利用专有的人工智能和基于物理的平台开创口服肽治疗药物开发的生物技术公司，今天宣布完成了超额认购的8900万美元的B轮融资。此轮融资由LAV和Foresite Capital共同领投，Quan Capital、Hankang Capital、RA Capital Management、Logos Capital以及包括OrbiMed在内的现有投资者参与。

Proceeds from the financing will support the advancement of Pinnacle's lead programs through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases, while further expanding the Company's proprietary peptide discovery platform and research and development capabilities.

融资所得将用于支持 Pinnacle 公司的主要项目推进至临床概念验证阶段，最初重点放在免疫学和心脏代谢疾病领域，同时进一步扩展公司专有的肽发现平台以及研发能力。

Pinnacle Medicines is developing a new generation of oral peptide medicines designed to deliver biologic-level safety and efficacy with the convenience of oral dosing..

Pinnacle Medicines 正在开发新一代口服肽类药物，旨在通过口服给药的便利性提供生物制品级别的安全性和有效性。

'This financing marks an important milestone for Pinnacle Medicines and reflects strong conviction in the transformative potential of oral peptide therapeutics,' said Jonathan Wang, Chief Executive Officer of Pinnacle Medicines. 'At Pinnacle, we are building a platform designed to unlock the full therapeutic potential of peptides through oral delivery.

“这笔融资标志着Pinnacle Medicines的一个重要里程碑，反映了对口服多肽治疗药物变革潜力的强烈信心，”Pinnacle Medicines首席执行官Jonathan Wang表示。“在Pinnacle，我们正在打造一个通过口服递送充分释放多肽治疗潜力的平台。”

With this strong group of investors, we are now focused on translating that vision into clinical proof of concept and delivering transformative medicines for patients.'.

有了这批强大的投资者，我们现在正专注于将这一愿景转化为临床概念验证，并为患者提供变革性的药物。

Chengzao Sun, Ph.D., Chief Scientific Officer and Co-Founder, added: 'We have assembled an experienced peptide drug discovery and development team spanning all key disciplines and built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics.

孙成造博士，首席科学官兼联合创始人补充道：“我们组建了一支经验丰富的肽类药物发现与开发团队，涵盖所有关键学科，并建立了一个专有平台，将新兴的人工智能技术与基于物理的模拟相结合，以合理设计和优化肽类治疗药物。”

The rapid progression of our pipeline reflects the strength of this approach and positions us to advance a new generation of oral peptide medicines for chronic diseases.'.

我们管道的快速进展反映了这种方法的优势，使我们能够为慢性疾病推进新一代口服肽类药物。

'We are very excited about the future of oral peptide therapeutics, and Pinnacle Medicines is emerging as a leader in this field,' said Cindy Xiong, Partner at Foresite Capital. 'The team brings deep experience in peptide drug development and has demonstrated a remarkable ability to rapidly build both a differentiated discovery platform and a promising first-in-class pipeline.

“我们对口服多肽治疗药物的未来感到非常兴奋，Pinnacle Medicines正成为这一领域的领导者，”Foresite Capital的合伙人Cindy Xiong表示。“该团队在多肽药物开发方面拥有深厚的经验，并展现了快速构建差异化发现平台和前景广阔的首创新药管线的卓越能力。”

We look forward to supporting the company as it accelerates these programs toward clinical development.'.

我们期待着支持该公司加速这些项目向临床开发迈进。

David Wang, M.D., Ph.D., Partner and Senior Managing Director at OrbiMed, added: 'We have supported Pinnacle Medicines since inception and have been impressed by the team's scientific vision and execution. Oral peptide therapeutics have the potential to reshape treatment paradigms across multiple disease areas, and we are excited to continue supporting the company as it advances its pipeline toward clinical proof of concept.'.

奥博资本合伙人兼高级董事总经理王大卫博士补充道：“我们从一开始就支持巅峰医药，并对团队的科学视野和执行力印象深刻。口服多肽治疗有潜力重塑多个疾病领域的治疗模式，我们很高兴在公司推进其管线至临床概念验证阶段时继续提供支持。”

About Pinnacle Medicines

关于巅峰医药

Pinnacle Medicines is a biotechnology company focused on developing a new generation of oral peptide therapeutics designed to deliver biologic-level efficacy with the convenience of oral dosing. The company is building a differentiated discovery platform that integrates physics-based molecular simulations, artificial intelligence - enabled design, and advanced peptide chemistry to rationally design and optimize peptide medicines.

Pinnacle Medicines是一家生物技术公司，专注于开发新一代口服肽类治疗药物，旨在通过口服给药的便利性实现生物制品级别的疗效。该公司正在构建一个差异化的发现平台，整合基于物理的分子模拟、人工智能辅助设计以及先进的肽化学，以合理设计和优化肽类药物。

Pinnacle is advancing a pipeline of potential first- and best-in-class oral peptide programs targeting validated pathways in immunology and cardiometabolic diseases..

Pinnacle正在推进一系列潜在的首个及最佳同类口服肽项目，这些项目针对免疫学和心代谢疾病中已验证的通路。

For more information, please visit

欲了解更多信息，请访问

www.pinnaclemedicines.com

。

About LAV

关于LAV

LAV is a global biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto. Originating in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off to become an independent investment management company in 2011. Our team of over 50 distinguished professionals, experienced in science, medicine, investment, and operations, embraces a culture of integrity, teamwork, diligence, and scientific rigor..

LAV是一家全球生物医学风险投资公司，在香港、上海和帕洛阿尔托设有办事处。公司起源于2008年，最初是礼来公司的企业风险投资子公司，于2011年独立成为一家投资管理公司。我们拥有超过50名杰出的专业人士，他们在科学、医学、投资和运营方面经验丰富，并秉持诚信、团队合作、勤奋和科学严谨的文化。

For more information, please visit

更多信息，请访问

www.lavfund.com

。

About Foresite Capital

关于富赛资本

Foresite Capital is a multi-stage healthcare, sciences and technology investment firm with more than $3 billion in assets under management. The firm addresses areas of great unmet need by funding promising businesses at all stages of their life cycles. Founded in 2011, Foresite Capital is based in the San Francisco Bay Area, Los Angeles, and New York City..

Foresite Capital是一家多阶段的医疗、科学和技术投资公司，管理着超过30亿美元的资产。该公司通过在企业生命周期的各个阶段资助有潜力的业务，来满足重大未满足的需求。Foresite Capital成立于2011年，总部位于旧金山湾区、洛杉矶和纽约市。

For more information, please visit

有关更多信息，请访问

www.foresitecapital.com

。

About OrbiMed

关于奥博资本

OrbiMed is a leading healthcare investment firm, with over $19 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.

奥博资本是一家领先的医疗保健投资公司，管理着超过190亿美元的资产。奥博资本通过私募股权基金、公共股权基金以及特许权/信贷基金，在全球范围内对医疗保健行业进行投资，从初创企业到大型跨国公司均有涉及。奥博资本力求成为首选的资本提供者，提供定制的融资解决方案和广泛的全球团队资源，以帮助建立世界级的医疗保健公司。

OrbiMed's team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets..

奥博资本超过130人的团队分布在纽约、伦敦、旧金山、上海、香港、孟买、赫兹利亚及其他关键的全球市场。

For more information, please visit

更多信息，请访问

www.orbimed.com

。

Corporate Contact

企业联系人

Yiou Chen

陈奕鸥

Pinnacle Medicines

巅峰医药

[email protected]